Anti- CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease

Leukemia and Lymphoma

Volumn 31, Issue 3-4, 1998, Pages 385-392

  Hartmann, Frank ^a   Renner, Christoph ^a   Jung, Wolfram ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Antibodies to CD16 CD30; Antibody therapy; Hodgkin's disease; Immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CD30 ANTIGEN; IMMUNOGLOBULIN ANTIBODY;

ADULT; ALLERGIC REACTION; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032436863     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059232     Document Type: Article

References (26)

1. DeVita, V.T. (1987) The consequences of chemotherapy of Hodgkin's disease: the 10th David A. Karnofsky Memorial Lecture. Cancer, 47, 1-13.
2. Milstein, C., Cuello, A.C. (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature, 305, 537-540.
3. Renner, C, Pfreundschuh, M. (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev., 145, 179-209.
4. Hombach, A., Jung, W., Pohl, C., Renner, C., Sahin, U., Schmits, R., Wolf, J., Kapp, U., Diehl, V., Pfreundschuh, M. (1993) CD16/CD30 bispecific antibody induces lysis of Hodgkin cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer, 55, 830-837.
5. Pohl, C, Denfeld, R., Renner, C., Jung, W., Bohlen, H., Sahin, U., Hombach, A., van Lier, R., Schwonzen, M., Diehl, V., Pfreundschuh, M. (1993) CD30-antigen-specific targeting and activation of T-cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int. J. Cancer, 54, 820-827.
6. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C., Triimper, L., Hartmann, F., Diehl, V., van Lier, R., Pfreundschuh, M. (1994) Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science, 264, 833-835.
7. Falini, B., Pileri, S., Pizzolo, G., Dürkop, H., Flenghi, L., Stirpe, F., Martelli, M.F., Stein, H. (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood, 85, 1-14.
8. Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., Pfreundschuh, M. (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood, 89, 2042-2047.
9. Investigator's handbook. A Manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program, DCT, NCI, Bethesda, MD 20892, USA, 1993
10. Pohl, C, Renner, C., Schwonzen, M., Sieber, M., Lorenz, P., Pfreundschuh, M., Diehl, V. (1992) Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal imase antibodies. Int. J. Cancer, 50, 958-967.
11. Blomberg, K., Ulfstedt, A.C. (1993) Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J. Immunol. Meth., 160, 27-38.
12. Bolhuis, R.L., Lamers, C.H., Goey, S.U., Eggermont, A.M., Trimbos, J.B., Stoter, G., Lanzavecchia, A., di Re, E., Miotti, S., Raspagliesi, F., Rivoltini, L., Colnaghi, M.I. (1992) Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer, 78 (Suppl 7), 78-81.
13. Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M.I., Di Re, E.M., Eggermont, A.M.M., Goey, S.H., Gratama, J.W., Lamers, C.H.J., Nooy, M.A., Parmiani, G., Raspagliesi, F., Ravagnani, F., Scarfone, G., Trimbos, J.B., Warnaar, S.O., Bolhuis, R.L.H. (1995) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J.Natl. Cancer Inst., 87, 1463-1469.
14. De Gast, G.C., Haagen, I.A., van Houten, A.A., Klein, S.C., Duits, A.J., de Weger, R.A., Vroom, T.M., Clark, M.R., Phillips, S., van Dijk, A.J., Bast, B.J.E.G. (1995) CDS T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother., 40, 390-396.
15. Kroesen, B.J., ter Haar, A., Spakman, H., Willemse. P., Sleijfer, D.T., de Vries, E.G., Mulder, N.H., Berendsen, H.H., Limburg, P.C., The, T.H., de Leij, L. (1993) Local antitumour treatment in carcinoma patients with bispecific monoclonal antibody redirected T cells. Cancer Immunol. Immunother., 37, 400-407.
16. Kroesen, B.J., Buter, J., Sleijfer, D.T., Janssen, R.A., van der Graaf, W.T., The, T.H., de Leij, L., Mulder, N.H. (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer, 70, 652-661.
17. Nitta, T., Sato, K., Yagita, H., Okumura, F., Ishii, S. (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335, 368-371.
18. 2 in ovarian carcinoma patients. Int. J. Cancer, 66, 477-483.
19. Valone, F.H., Kaufman, P.A., Guyre, P.M., Lewis, L.D., Memoli, V., Deo, Y., Graziano, R., Fisher, J.L., Meyer, L., Mrozek-Orlowski, M., Wardwell, K., Guyre, V., Morley, T.L., Arvizu, C., Fanger, M.W. (1995) Phase Ia/Ib trial of bis pecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu. J. Clin. Oncol., 13, 2281-2292.
20. Curnow, R.T., Pfister, D.G., Deo, Y., Motzer, R.J., Winston, C, Keeperman, K.L., Malone, T. (1997) A phase I trial of bispecific antibody (BsAB) MDX447 without and with granulocyte colony-stimulating factor (G-CSF) in patients with adult solid tumors. Proc. Am. Soc. Clin. Oncol., 16, 1571 (abstract).
21. Weiner, L.M., Clark, J.I., Davey, M., Li, W.S., de Palazzo, I.G., Ring, D.B., Alpaugh, R.K. (1995) Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FCγRIII. Cancer Res., 55, 4586-4593.
22. Clark, J.I., Alpaugh, R.K., von Mehren, M., Schultz, J., Gralow, J.R., Cheever, M.A., Ring, D.B., Weiner, L.M. (1997) Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol. Immunother., 44, 265-272.
23. Lamers, C.H.J., Gratama, J.W., Warnaar, S.O., Stoter, G., Bolhuis, R.L.H. (1995) Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAB-targeted activated T-lymphocytes. Int. J. Cancer, 60, 450-457.
24. Hartmann, F., Renner, C, Tembrink, S., Held, G., Ames, M., Jung, W., Pfreundschuh, M. (1998) Treatment of refractory Hodgkin's disease (HD) with an anti- CD30/CD16 bispecific monoclonal antibody (BiMAb). Proc. Am. Soc. Clin. Oncol., 17, 60 (abstract).
25. Holliger, P., Prospero, T., Winter, G. (1993) Diabodies: Small bivalent and bispecific antibody fragments. Proc. Natl.Acad. Sci. USA, 90, 6444-6448.
26. Mack, M., Riethmüller, G., Kufer, P. (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl.Acad. Sci. USA, 92, 7021-7025.